Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002882170 | SCV003242180 | uncertain significance | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 827 of the EVC2 protein (p.Arg827Cys). This variant is present in population databases (rs373953980, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with EVC2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004065960 | SCV004865420 | uncertain significance | Inborn genetic diseases | 2024-01-03 | criteria provided, single submitter | clinical testing | The c.2479C>T (p.R827C) alteration is located in exon 14 (coding exon 14) of the EVC2 gene. This alteration results from a C to T substitution at nucleotide position 2479, causing the arginine (R) at amino acid position 827 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |